Abstract:

Intrahepatic cholestasis of pregnancy (ICP), an idiopathic liver disease in pregnancy, is characterized by pruritus and the elevated level of serum bile acid, which can lead to the adverse perinatal outcomes and even fetal death. This review systematically summarizes the research progress in the genomics, transcriptomics, proteomics, and metabolomics of ICP, revealing its complex molecular mechanisms and various novel biomarkers. Drug therapy of ICP focuses on the existing first-line drug: ursodeoxycholic acid, supplemented by new drugs such as rifampicin and integrated traditional Chinese and Western medicine therapy. The AI-driven nonlinear prediction models, integrating high-risk factors with clinical and laboratory data, may provide powerful decision-making tools for the early prediction, intervention, and personalized management of ICP. Multidisciplinary management emphasizes the importance of comprehensive ICP care from the perspectives of obstetrics, hepatology, and nutritional metabolism. Future research should integrated the artificial intelligence and big data, the construction of accurate prediction models, the preventive intervention strategies and the long-term management of maternal and infant health, so as to improve the adverse perinatal outcomes.

Key words: Cholestasis, intrahepatic, Pregnancy women, Epigenomics, Biomarkers, Predictive model, Clinical Governance